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Abstract
Xp11.2 translocation carcinoma is a distinct subtype of renal cell carcinoma characterized by translocations involving the TFE3
gene. Our study included the morphological, immunohistochemical and clinicopathological examination of 28 Xp11.2 RCCs.
The immunophenotype has been assessed by using CA9, CK7, CD10, AMACR, MelanA, HMB45, Cathepsin K and TFE3
immunostainings. The diagnosis was confirmed by TFE3 break-apart FISH in 25 cases. The ages of 13 male and 15 female
patients, without underlying renal disease or having undergone chemotherapy ranged from 8 to 72. The mean size of the tumors
was 78.5 mm. Forty-three percent of patients were diagnosed in the pT3/pT4 stage with distant metastasis in 6 cases. Histological
appearance was branching-papillary composed of clear cells with voluminous cytoplasm in 13 and variable in 15 cases, including
one tumor with anaplastic carcinoma and another with rhabdoid morphology. Three tumors were labeled with CA9, while CK7
was negative in all cases. Diffuse CD10 reaction was observed in 17 tumors and diffuse AMACR positivity was described in 14
tumors. The expression of melanocytic markers and Cathepsin K were seen only in 7 and 6 cases, respectively. TFE3 immuno-
histochemistry displayed a positive reaction in 26/28 samples. TFE3 rearrangement was detected in all the analyzed cases (25/
25), including one with the loss of the entire labeled break-point region. The follow-up time ranged from 2 to 300 months, with 7
cancer-related deaths. In summary, Xp11.2 carcinoma is an uncommon form of renal cell carcinoma with a variable
histomorphology and rather aggressive clinical course.
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Introduction
In the current classification scheme there are 13 distinct types
of renal cell carcinoma (RCC), and one of them is the Xp11.2
translocation RCC. It is a rare subtype and is characterized by
different translocations involving the transcription factor 3
gene (TFE3), that leads to a new fusion gene encoding an
aberrant transcription factor [1]. Five common partner genes
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were identified including ASPL-TFE3: t(X;17)(p11.2;q25),
PSF - TFE3 : t ( X ; 1 ) ( p 11 . 2 ; p 3 4 ) , PRCC - TFE3 :
t(X;1)(p11.2;q21), CLTC-TFE3: t(X;17)(p11.2;q23) and
NonO-TFE3: t(X)(p11.2q12) so far in the literature [2–5].
Although Xp11.2 RCC was described as a malignancy among
children and adolescents, cases from adults and elders were
also reported [6, 7]. The prognosis is controversial, since
Xp11.2 RCC has an indolent behavior in children, however,
new reports on an aggressive clinical course in adults has been
reported as well [6, 8]. Tumor cells usually have blank cyto-
plasm that mimics clear cell RCC, although the growth pattern
is frequently papillary, with psammoma bodies often present
[9]. Xp11.2 RCC displays negativity with carbonic anhydrase
9 (CA9) and CK7 [10, 11], while CD10 is often positive and
the expression of the melanocytic markers (MelanA and
HMB45) are frequent, although they are not expressed in oth-
er subsets of RCC [6]. Cathepsin K is a novel marker for
Xp11.2 RCC and its positivity indicates the presence of fusion
gene PRCC-TFE3 [12]. The result of translocations involving
the TFE3 gene is the overexpression of the TFE3 protein that
can be detected by immunohistochemistry [13]. Although nu-
clear positivity of the TFE3 protein is a useful diagnostic
marker, false negativity and positivity may occur, therefore
the identification of the TFE3 gene rearrangement by fluores-
cent in situ hybridization (FISH) is needed to confirm the
diagnosis [13]. The prognosis of Xp11.2 RCC is still unclear
because of the low appearance of series including a great
number of patients and the short follow-up period [6]. The
three main aims of this retrospective study were: (1) to deter-
mine the frequency of Xp11.2 RCC in a large set of surgically
treated renal tumors; (2) to provide detailed survival data; and
(3) to analyze the morphological features with immunohisto-




A retrospective study was performed that included morpho-
logical, immunohistochemical and molecular pathological
analysis. The cases were collected from the Department of
Pathology, University of Szeged (1512 own and 64 consulta-
tion cases), the 2nd Department of Pathology, Semmelweis
University (818 cases), and the 1st Department of Pathology
and Experimental Cancer Research, Semmelweis University
(404 cases). The diagnostic criteria for Xp11.2 RCC were the
typical morphological pattern or moderate-to-strong nuclear
positivity with TFE3 immunohistochemistry or a positive
TFE3 break-apart FISH analysis. A total of 28 cases of
Xp11.2 RCC were diagnosed from 2804 tumors in the three
cen t e r s . A l l t umor s we r e s e l e c t ed f o r fu r t he r
immunohistochemical analysis. The main clinical data includ-
ed age, sex and symptoms at the time of the diagnosis. Follow-
up data were collected from the general practitioners, patient
records as well as the patient database of the University of
Szeged and Semmelweis University. Tumor size and AJCC
TNM stage were obtained from the original histopathological
report, however, the TNM stage was amended according to
the eighth edition of AJCC TNM staging. All the
hematoxylin-eosin stained slides were reviewed by three pa-
thologists (LK, ÁS, TM) to reevaluate the grade according to
the ISUP criteria, the histological pattern (generally papillary
or solid pattern) and to estimate the percentage of the cellular
morphology (predominantly clear or eosinophilic cells). The
presence of foamy cells, intracellular pigment, cholesterol
clefts, necrosis and psammoma bodies were also recorded,
though the extent of necrosis was not scored.
Immunohistochemistry (IHC) and Tissue Microarray
(TMA)
The IHC reactions were carried out on TMA. The recipient
TMA block was constructed by using a TMA Master
(3DHISTECH Ltd., Budapest, Hungary). Stated briefly, from
the most representative paraffin blocks of the tumors, two
cylindrical cores of 2 mm in diameter were punched out man-
ually. For IHC labeling a panel of antibodies listed in Table 1
was used. Only membrane labeling for CA9, and nuclear la-
beling for TFE3 was treated as positive. The scoring was
performed in a semiquantitative manner and the cases were
classified into three categories, namely negative (no staining
or less than 5% of positive cells), focally positive (5–75% of
positive cells) and diffusely positive (76–100% of positive
cells).
TFE3 Break-Apart FISH Analysis
Fluorescent in situ hybridization assays were carried out
to detect TFE3 gene rearrangement. Four μm thick sec-
tions were cut from the TMA blocks. The sections were
deparaffinized and the reaction was carried out by using
ZytoLight® SPEC TFE3 dual color break-apart FISH
probe (ZytoVision GMBH, Bremerhaven, Germany) ac-
cording to the manufacturer’s instructions. The slides
were counterstained with 4′, 6-diamidino-2-phenylindole
(DAPI, Abbott Laboratories, Abbott Park, IL, USA) and
scanned with a Pannoramic Midi s l ide scanner
(3DHISTECH Ltd., Budapest, Hungary). The evaluation
wa s p e r f o rmed by u s i ng Panno r am i c Vi ewe r
(3DHISTECH Ltd., Budapest, Hungary). One hundred
nuclei were counted and FISH reaction was considered
positive when over 10% of the neoplastic nuclei displayed
TFE3 rearrangement.
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Results
Twenty-eight tumors proved to be Xp11.2 RCC among 2804
nephrectomies reviewed by the three pathology departments
(0.99%). The diagnosis was suspected mainly because of the
histological appearance. The diagnosis was later confirmed by
IHC in each case and by FISH analysis except for patient #11,
#12 and #24.
Clinical Data and Follow-Up
The clinicopathological findings are summarized in Table 2.
Thirteen male and fifteen female patients were included in our
cohort. The median age was 60 years (with range from 8 to
72). Three tumors occurred in children andWilms’ tumor was
suspected in all cases. The tumor produced symptoms in 9
patients; in patient #22 a severe pain was provoked by distant
bone metastasis. The tumor was an incidental finding in 7
patients. There were no underlying renal disorders in any pa-
tients in the affected kidney, but in patient #12 contralateral
kidney agenesis was present. None of the examined patients
had received chemotherapy or had had previous malignant
tumors, although pharyngeal carcinoma developed in patient
#2 after the nephrectomy.
Radical nephrectomy was performed in each case except
three patients, who were treated with nephron-sparing ne-
phrectomy (tumor resection) because of the relatively small
tumors (patient #7 and #8) or the absence of the contralateral
kidney (patient #12).
Follow-up information was accessible in 21/28 patients
and the mean follow-up time was 51 months (with range from
2 to 321 months). Regional lymph node or distant metastasis
developed in 13 patients (9 had been discovered before sur-
gery; 6 distant and 3 regional lymph node metastases). Seven
patients died from cancer-related causes and one patient died
from a non-cancer-related cause. In patient #15 a regional
lymph node metastasis developed after 12 months so she
was treated with retroperitoneal lymphadenectomy and at the
last follow-up there were no signs of the disease. However,
60 months after the nephrectomy, patient #14 had multiple
pulmonary, hepatic and bone metastases. He received tyrosine
kinase and mTOR inhibitors until treatment failure. In patient
#27multifocal vertebral metastases developed. She is current-
ly receiving tyrosine kinase therapy and stable. The remaining
11 patients were alive with no evidence of disease.
Morphological Aspects
All the examined tumors were unilateral and unifocal. The
largest diameter of the tumors ranged from 15 mm to
160 mm and the average was 78.5 mm. In two cases the actual
size of the tumor was unknown. Macroscopically the cut sur-
face was usually solid and cystic with sulfur yellow color, as
seen in clear cell RCC. Foci of necrosis or hemorrhage were
occasionally noted as well. The invasion of the renal vein,
sinus and adipose capsule was observed in 7, 8, 6 cases re-
spectively. The predominant architectural appearance was sol-
id pattern (13/28), followed by papillary pattern (11/28), while
both solid and papillary patterns were seen in a small propor-
tion of cases (4/28). Tumors were composed mostly of clear
cells in 19 cases, mostly of eosinophilic cells in 7 cases and
mixed clear cell and eosinophilic morphology was seen in 2
cases. Twenty-two cases had typical architecture with volumi-
nous clear cytoplasm, nested or papillary growth. The remain-
ing 6 cases had diverse architecture, mostly mimicking clear
cell RCC, except for patient #5, whose tumor resembled
rhabdoid morphology and patient #6, whose tumor had ana-
plastic carcinoma appearance. The presence of foamy cells,
intracytoplasmic pigment, cholesterol clefts, psammoma bod-
ies and necrosis were observed in 7, 4, 1, 11 and 17 cases
respectively. Most of the tumors had high-grade nuclear fea-
tures (19/28). Detailed summary of the microscopic findings
can be found in Table 3. Figures 1 and 2 include representative
images of the morphological features.
IHC Findings
Results of immunohistochemistry are summarized in Table 4
and representative pictures are presented on Fig. 3. Three
cases displayed positivity with CA9, although two of these
were necrotic tumors. All the examined cases were negative
with CK7, while CD10 was strongly positive in 17 cases.
Table 1 List of the antibodies
used in the study Antibody Clonality/Source/Clone Concentration
CA9 rabbit polyclonal, Novus Biologicals 1/2000
CK7 mouse monoclonal, Cell Marque, OV-TL 12/30 1/100
CD10 mouse monoclonal, Biocare Medical, CM129 1/50
AMACR rabbit polyclonal, Abcam 1/100
MelanA mouse monoclonal, Labvision, A103 1/200
HMB45 mouse monoclonal, Cell Marque, hmb-45 1/200
TFE3 rabbit monoclonal, Cell Marque, mrq-37 1/100
Cathepsin K mouse monoclonal, Abcam, 3f9 1/100
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AMACR was negative in 14 tumors and a diffuse-to-focal
positivity was seen in the remaining 14 cases. The diagnostic
TFE3 reaction strongly labeled the nuclei in 26/28 cases, how-
ever, Cathepsin K displayed positivity only in 6 tumors.
MelanA was positive in four cases and HMB45 showed a
weak-to-diffuse positivity in three patients.
FISH Findings
FISH reaction was performed in 25 cases, because in pa-
tient #11, #12 and #24, the quality of tumor tissue was not
appropriate for proper molecular analysis. For the above-
mentioned three cases, FISH was repeated using the
original paraffin blocks, although the test remained unsuc-
cessful. In 21 tumors typical split signals were seen
(Fig. 4 A), while in patient #9 and #10 truncated signal
pattern was mostly observed (Fig. 4 B). In patient #14,
signals were separated, even though they were unusually
close to each other (Fig. 4 C). In patient #23 (a female) an
entire break-point region was completely absent (Fig. 4
D). Hence in this case only one signal pair was detected
in the nuclei of the tumor cells, while in the surrounding
renal parenchyma two unaffected signal pairs were pres-
ent. The immunophenotype and histomorphology led us
to classify the case as Xp11.2 RCC. No other abnormal-
ities were seen by using FISH in any cases.
Table 2 Clinicopathological features of the patients
Age (y) Sex Symptoms† Side Size (mm) pT Stage Node Status§ Metastasis or recurrence* Follow-up (mo) Status
1 52 M – L 70 4 – – – LTF
2 69 M Incidental finding on CT L 50 1b – – – LTF
3 47 M Hematuria, flank pain R 100 3b Neg Lung, Liver 2 DOD
4 69 F Hematuria R 80 3a – Bone-U, Local R 53 DOD
5 59 M Flank pain L 140 4 Pos – – LTF
6 67 M Fatigue, subcostal pain L 160 4 Pos Liver, LN 2 DOD
7 40 M – L 25 1a – None 127 NED
8 15 F Palpable ventral mass L 55 1b – Lung, Vertebral column 14 DOD
9 46 M Incidental finding L 100 2a Neg Local R 13 DOD
10 72 F Flank pain L 140 3a – – 4 DOD
11 21 F – R – 3a – – – LTF
12 14 M – L – 1a – None 12 NCRD
13 31 M Incidental finding on US L 55 1b – None 87 NED
14 57 M – L 100 3a Neg Lung, Liver, Vertebral column 81 DOD
15 40 F – R 110 3a – LN 65 NED
16 50 F – R 45 1b – None 31 NED
17 32 M Incidental finding B 15 1a – None 24 NED
18 60 F Incidental finding – 16 1a – – – LTF
19 66 F – R 60 1b Pos Adrenal gland – LTF
20 32 M – R 20 1a Pos Liver – LTF
21 17 F – R 35 1a – None 175 NED
22 36 F Shoulder pain R 120 3b – Scapula 13 AWD
23 40 F Incidental finding R 41 1b – None 24 NED
24 8 F Palpable ventral mass L 100 2b – – 321 NED
25 54 F – R 120 3a Neg None 10 NED
26 66 M Abdominal pain L 110 2b – None 4 NED
27 51 F – R 65 1b – Vertebral column 3 AWD
28 46 F Incidental finding L 110 3a Pos None 7 NED
†Symptoms: including any tumor-related symptoms; incidental finding indicates a symptomless tumor; −, no data. pT Stage: classification by AJCC
2016 TNM Staging System. §Node Status: nodal status at time of surgery; −, no lymph node was removed; Neg, negative; Pos, positive. A lymph node
metastasis that developed during the follow-up period is listed in the”Metastasis” column. *Metastasis: either found earlier or at the same time with the
primary renal tumor, or during the follow-up period; Bone-U, bone, exact location is unknown; −, no data; R, recurrence; LN, lymph node. ¶Status:
DOD, died of disease; LTF, patient is deceased, but lost to follow-up; NED, no evidence of disease; NCRD, not a cancer-related death; AWD, alive with
disease; −, no data
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Discussion
Clinicopathological Findings of Xp11.2 RCC
We reviewed 2804 nephrectomy cases and identified 28
Xp11.2 translocation RCCs. In our cohort its frequency was
lower, compared to literature data (0.99 vs. 1–4%) [22]. That
is due to the relatively large number of patients included in our
study, the analysis may roughly represent the ratio of Xp11.2
RCC in Hungary. In these neoplasms the characteristic cyto-
genetic change is the translocation involving the MIT family
transcription factor TFE3 gene [1]. These tumors were once
regarded as childhood malignancies, though because of the
significant overlapping features with clear cell and papillary
RCC and the limited cytogenetic data, some authors suggested
that the exact frequency in adults is underestimated [14]. In
our cohort 12 tumors occurred in patients who were less than
40 years old, only four tumors affected children, and the oldest
patient examined was 72 years old. Nine patients were symp-
tomatic and tumor-related pain was the most common symp-
tom. Only seven tumors did not produce any noticeable signs.
A link between previous use of chemotherapy and transloca-
tion RCC was reported [15], but in our study there was no
patient with a prior history of malignancy. Discriminating
Xp11.2 RCC from other subtypes of RCC is crucial for prog-
nostic and predictive reasons. It was suggested recently, that
patients with Xp11.2 RCCmay benefit frommTOR inhibitors
and VEGF-targeted agents [16, 17]. The diagnosis relies on
morphological features, immunohistochemical findings and
molecular pathological analysis. Xp11.2 RCC has no specific
macroscopic appearance; in fact most tumors resemble clear
cell RCC with a sulfur yellow cut surface along with foci of
hemorrhage and/or necrosis [9]. Xp11.2 RCC is usually diag-
nosed as a sizeable mass in the kidney. The mean size of our
tumors (78.5 mm) was larger than in the earlier reported series
[2, 14, 18]. In our previous analysis, only unclassified RCC
Table 3 Histological findings of










IP ChC PB Necrosis ISUP
grade
1 5 95 50 50 – – – – + 4
2 40 60 30 70 + + – – – 2
3 1 99 20 80 – – – – + 4
4 50 50 90 10 – – – – + 2
5 – 100 10 90 – – – – + 4
6 – 100 5 95 – – – – + 4
7 – 100 100 – – – – – – 1
8 90 10 80 20 – – – – – 2
9 50 50 70 30 – – – – + 4
10 80 20 75 25 – – – – + 4
11 95 5 90 10 + – – – – 3
12 50 50 80 20 – – – + + 3
13 100 – 100 – + – + + + 2
14 10 90 60 40 – + – + – 2
15 80 20 70 30 – + – – + 3
16 90 10 75 25 + – – + – 3
17 100 – 100 – – – – + – 2
18 5 95 30 70 + – – + – 3
19 10 90 80 20 – – – + + 2
20 – 100 95 5 – – – + + 4
21 – 100 30 70 – – – + – 2
22 50 50 90 10 – – – – + 3
23 – 100 80 20 + – – – + 3
24 – 100 60 40 – – – – – 3
25 80 20 30 70 + – – + + 3
26 95 5 90 10 – + – – + 3
27 100 – 50 50 – – – + – 3
28 90 10 80 20 – – – – + 3
PP, indicates papillary pattern; SP, solid pattern; CCs, clear cells; ECs, eosinophilic cells; IP, intracytoplasmic
pigment; ChC, cholesterol clefts; PB, psammoma bodies; +, present; −, absent
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and collecting duct carcinoma were larger than Xp11.2 RCC
[19]. An invasion of the renal vein and/or the sinus is quite
frequent; at least one of these was noticed in 12 patients.
Metastatic spread to the regional lymph nodes or distant or-
gans was observed in 32% of the cases; six patients had ne-
phrectomy at the pM1 stage. Our observations on the rate of
pT3/pT4 stage and the occurrence of metastasis are in accor-
dance with the literature data [14]. This late stage discovery
might partly explain the generally poor outcome in Xp11.2
RCC.
Microscopic Features of Xp11.2 RCC
Microscopically the predominant growth patterns are papil-
lary, tubular, nested and mixed. A striking histological finding
is the presence of psammoma bodies [2, 18]. A different dis-
tribution was observed in our cohort, as a result of solid pat-
tern observed as most frequent, followed by papillary and
mixed architecture. Tumors were composed of mainly clear
cells in 19 and of eosinophilic cells in 7 cases. Additionally the
simultaneous presence of both cell types was noted in two
Fig. 1 Representative images of
typical morphological features of
Xp11.2 renal cell carcinomas. (A)
Solid-nested pattern with
admixture of eosinophilic and
clear cells. (B) Alveolar pattern
populated by eosinophilic cells.
Psammoma bodies are also
present. (C) Papillary pattern with
voluminous clear cells and
psammoma bodies. D
Occasionally the nuclei are near
the apical surface of the cells and
they mimic clear cell papillary
renal cell carcinoma. The arrows
indicate the psammoma bodies.
All images have a magnification
factor of 200x
Fig. 2 Representative images of
Xp11.2 renal cell carcinomaswith
unusual morphological features.
(A) Tubular pattern resembling
low-grade clear cell carcinoma.
(B) Solid pattern with foci of
comedo-like necrosis. (C)
Rhabdoid tumor-like pattern. (D)
Anaplastic carcinoma
appearance. All images have a
magnification factor of 200x
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cases. Psammoma bodies were observed in 11 cases. Foamy
cells and intracytoplasmic pigment are common features in
papillary RCC; hence their extensive presence can cause dif-
ferential diagnostic problems. However, in our cohort both
foamy cells and intracytoplasmic pigment occurred in a small
proportion of cases and they did not have a predominant
papillary pattern. Microscopic tumor cell necrosis was ob-
served in 60% of tumors. Although the effect of necrosis on
the outcome in Xp11.2 RCC is doubtful, in a large set of RCC
patients, poor prognostic effect of microscopic tumor necrosis
was identified earlier in the three most frequent types of RCC
[20]. Cases with atypical architecture can cause serious
Table 4 Immunohistochemical
results of the analyzed cases CA9 CK7 CD10 AMACR MelanA HMB45 Cathepsin K TFE3 IHC TFE3 FISH
1 N N D N N N N D +
2 N N D N N N N D +
3 N N N N N N N D +
4 N N D D N N D D +
5 N N D N N N N D +
6 N N N N N N N D +
7 N N D F N N N D +
8 N N D D N N N D +
9 N N N N N N N D +
10 N N D N D N N D +
11 N N D F N N F F NA
12 N N D D N N N D NA
13 N N D D N D N D +
14 N N D D N F D D +
15 N N N N D N N D +
16 N N D D N N N D +
17 N N D F N N N D +
18 N N F D N N N F +
19 N N F N N N N D +
20 F N N N N N N N +
21 N N D N N D D D +
22 N N F D N N F D +
23 N N N N N N N D +
24 N N N N D N N F NA
25 N N D D N N N F +
26 N N D D F N F F +
27 F N D N N N N N +
28 F N F F N N N D +
N, indicates negative; F, focally positive; D, diffusely positive; NA, data not available
Fig. 3 Representative images of
the immohistochemical features
of the analyzed tumors. (A)
Tumor cells display diffuse TFE3
nuclear positivity. (B) Cathepsin
K expression in an Xp11.2 renal
cell carcinoma. (C) Diffuse
cytoplasmic and membranous
CD10-positivity is frequently
seen in Xp11.2 renal cell
carcinomas. (D) MelanA
expression in Xp11.2 renal cell
carcinoma. All images have a
magnification factor of 200x
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diagnostic difficulties; namely, the morphological spectrum of
Xp11.2 RCC is quite broad, furthermore urothelial cell carci-
noma mimicking translocation RCC was reported as well
[13]. In our cohort, a case mimicking anaplastic carcinoma
and another with rhabdoid morphology were observed.
Some authors suggested that the specific translocation has an
influence on histological appearance [21]. Because of the ab-
sence of fusion partner analysis, we cannot argue for or against
this statement. The influence on the prognosis of the fusion
partner is yet unclear [23].
Immunophenotype of Xp11.2 RCC
Xp11.2 RCC is negative with CA9, CK7 and positive
with CD10 and AMACR [10]. In our series, both CA9
and CK7 were completely negative in almost every
case, except for CA9 in three samples. However, two
of these tumors were extensively necrotic, therefore we
concluded that the staining was related to hypoxia of
the tumor tissue. Diffuse CD10 labeling was noted in
60% of cases, while AMACR-positivity was observed
only in 50% of the tumors. MelanA and HMB45 ex-
pression is frequent in TFEB translocation RCC, never-
theless is rare in Xp11.2 translocation RCC [5]. Similar
proportion was described in our cohort; namely, MelanA
and HMB45 were posi t ive in 4 and 3 tumors
respectively. For the diagnosis of Xp11.2 RCC, TFE3
immunostaining is the most frequently used method.
The specificity and sensitivity of the immunohistochem-
istry were found to be 99.6% and 97.5% [24], although
in some cases false negativity and false positivity can
occur [23, 25]. Argani et al. described that the shorter
incubation time with automated detection system made
TFE3 IHC more sensitive, while the specificity of the
reaction decreased. For the false-negative results, some
authors declared that it can be caused by preanalytical
factors (e.g. fixation time) or by different analytical
methodologies applied (e.g. poor-quality antibodies and
inappropriate antigen retrieval) [13, 26]. There were on-
ly two tumors (patient #20 and #27) with TFE3-nega-
tivity and the remaining cases displayed a diffuse and
strong nuclear positivity. Therefore, in our analysis the
sensitivity of TFE3 immunohistochemistry correlates
with data of the earlier reports [24]. Cystine protease
Cathepsin K is a novel immunohistochemical marker
for Xp11.2 RCC, although the expression depends on
the fusion partner of the TFE3. This can serve as an
explanation of its expression in only approximately 60%
of Xp11.2 RCC [12, 27]. Six cases with Cathepsin K-
positivity were described, that is slightly under the re-
ported rate in literature [13]. The difference might be
related to the different translocation partners.
Fig. 4 Representative images of
the signal patterns seen in the
analyzed tumors. (A) Typical split
signals (red and green arrows) are
present in a male patient (patient
#17). (B) Truncated signal pattern
consisting of a pair of fused
signals (yellow arrows) and a
single red signal was observed in
patient #10. (C) Although signals
are separated (red and green
arrows), they are unusually close
to each other. In lymphocytes
normal fused signals (yellow
arrows) are present (patient #14).
(D) The loss of an entire break-
point region was observed in
patient #23. The yellow arrow
indicates the intact chromosome
X
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Genetic Markers of Xp11.2 RCC
Reverse transcription polymerase chain reaction (RT-PCR) is
a sensitive method for the identification of different kinds of
chimeric mRNA transcripts, though the limited availability of
frozen samples generally makes the testing problematic or
even impossible [28]. Cytogenetic karotyping is another clas-
sic methodology for recognizing structural changes among
chromosomes. Nevertheless it requires a special laboratory,
technicians and fresh material, hence the use of karotyping
in the routine diagnosis of solid tumors is limited. Currently
next-generation sequencing can be used to reveal the partner
genes and identify new ones, as Pei et al. did [29]. FISH
reactions have been performed on FFPE samples with satis-
factory for some time now. TFE3 break-apart FISH assay was
introduced in 2011 and since that it has become an indispens-
able diagnostic tool for Xp11.2 RCC [13, 30]. In our study the
diagnosis was supported with TFE3 break-apart FISH analy-
sis in 25 cases. The classic break-apart pattern was observed in
21 tumors and the truncated signal pattern was noted in 2
cases. For the latter cases, two explanations exist. First of
all, truncation effect of cutting the tumor cell nuclei is a
well-known problem in FISH assays on FFPE slides [13].
On the other hand, in our cases this was the dominant pattern.
In patient #9 a single red signal was seen in 100% of the
positive tumor cells, while in patient #10 split and a single
red signal was observed in 17% and 83% of the positive tumor
cells respectively. Therefore it is considered by our team that
the labeled part of the TFE3 was lost due to an atypical break
in the gene sequence. Atypical FISH patterns are known for
both epitheloid renal neoplasia along with soft tissue sarcomas
[30–32]. In patient #14 the signals were unusually close to
each other, and this phenomenon is the indicative of
intrachromosomal inversion [4]. In a female patient an entire
break-point region was completely missing from the majority
of the tumor cells. This was considered to be a result of an
atypical translocation. Otherwise, the histomorphology and
immunophenotype were concordant with Xp11.2 RCC, so
the final diagnosis was made on summary of the above-
mentioned results. Such signal pattern was presumed earlier
[30], though to our best knowledge, this is the first report of
such a signal pattern in Xp11.2 RCC. Optimized TFE3 break-
apart FISH assay is extremely useful in routine diagnosis and
pathology consultation [27]. However, FISH analysis has its
own limitations as well, whereas poor fixation, inappropriate
hybridization, and/or extensive contamination with normal
stromal cells can lead to negative results. It must be stated that
b r e ak - apa r t F ISH te s t ha s l ow sens i t i v i t y fo r
intrachromosomal or paracentric inversions like in RBM10-
TFE3 and NonO-TFE3 RCCs [33]. In these cases, despite
the typical microscopic appearance and the characteristic
immunophenotype, FISH can provide equivocal or even neg-
ative results. In this particular scenario, one must be really
cautious about setting the diagnosis as Xp11.2 RCC, and fu-
sion partner analysis (if available) by RT-PCR or RNA se-
quencing should be considered [33].
Clinical Course of Xp11.2 RCC
Some authors previously reported that Xp11.2 RCC had an
indolent course [35–38]. Camparo et al. calculated a mortality
rate of 13.6% for Xp11.2 RCC from their analysis and litera-
ture data, although the follow-up period was quite short [14].
A fascinating case of Xp11.2 RCC was reported by Mangel
et al. [38]. In their report, rapid progression of a stable disease
was noted after the patient became pregnant, and the authors
considered that the enormous tumor evolution was triggered
by cytokines and hormones produced by the placenta, espe-
cially human chorionic gonadotropin. In our cohort the medi-
an follow-up time was 14 months. In the meantime, 33% of
the patients died from a cancer-related cause. This indicates
the fact that Xp11.2 RCC has the same mortality rate as the
calculated rate for overall RCC patients [39].
The strength of our study is the relatively high number of
systematically analyzed cases by descriptive light-microsco-
py, a panel of immunohistochemistry and FISH analysis. Two
tumors with a fairly unusual morphology was included, one
with anaplastic carcinoma appearance and another with
rhabdoidmorphology. Unique FISH pattern with the complete
loss of the labeled break-point region was observed. The clin-
ical follow-up was not complete for all patients, however, the
mean follow-up period was more than 4 years.
One limitation of this current study is the absence of cyto-
genetic studies and the data for fusion partner analysis.
In summary, the results of 28 Xp11.2 RCC cases were
presented from a large surgically treated series of RCC.
Xp11.2 RCC is a rare form of renal cell carcinoma; and it is
accounted for 0.99% of all RCC cases in our study. In adults
the outcome is rather poor. Cases with an unusual
histomorphology may cause differential diagnostic problems,
though the use of antibodies in combination can improve the
diagnostic performance. Finally, to avoid false negative and
false positive cases, the use of TFE3 break-apart FISH studies
and/or fusion partner analysis are strongly recommended.
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